Hematopoietic Stem Cell Transplantation for Autoimmune Disease

Area of Science:

• Immunology
• Hematology
• Rheumatology

Background:

• Biologic therapies offer targeted treatment for autoimmune diseases (ADs) but are not curative and require continuous administration.
• Hematopoietic stem cell transplantation (HSCT) has emerged as a potentially curative, one-off procedure for select AD patients.
• The European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) has significantly contributed to HSCT advancements for ADs.

Purpose of the Study:

• To review the role and efficacy of HSCT in treating autoimmune diseases.
• To highlight the shift from continuous immunosuppression to potentially curative HSCT.
• To underscore the growing evidence base for autologous HSCT in specific ADs.

Main Methods:

• Review of data and registrations from the EBMT ADWP, encompassing over 3,300 HSCT procedures for ADs.
• Analysis of recent evidence supporting autologous HSCT in conditions like multiple sclerosis, systemic sclerosis, and Crohn's disease.
• Evaluation of HSCT as an integral part of treatment algorithms for various ADs.

Main Results:

• HSCT aims to achieve treatment-free remissions by reinducing self-tolerance, contrasting with chronic suppression from biologics.
• Autologous HSCT shows improved evidence for efficacy in multiple sclerosis, systemic sclerosis, and Crohn's disease.
• HSCT is increasingly recognized as a viable treatment option for a spectrum of autoimmune diseases.

Conclusions:

• HSCT represents a paradigm shift in managing autoimmune diseases, offering a potential one-off, curative approach.
• The evidence base for autologous HSCT in ADs is strengthening, integrating it into treatment protocols.
• HSCT provides a promising alternative for patients with autoimmune diseases where conventional therapies are insufficient.